MERS-CoV: Understanding the Latest Human Coronavirus Threat

Aasiyah Chafekar and Burtram C. Fielding*

Molecular Biology and Virology Research Laboratory, Department of Medical Biosciences, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Robert Sobukwe Drive, Bellville, Western Cape, South Africa, 7535

*Correspondence: bfielding@uwc.ac.za; Tel.: +27-21-959 3620

Abstract: Human coronaviruses cause both upper and lower respiratory tract infections in humans. In 2012 a sixth human coronavirus (hCoV) was isolated from a patient presenting with severe respiratory illness. The 60-year-old man died as a result of renal and respiratory failure after admission to a hospital in Jeddah, Saudi Arabia. The aetiological agent was eventually identified as a coronavirus and designated Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV has now been reported in more than 27 countries across the Middle East, Europe, North Africa and Asia. As of July 2017, 2040 MERS-CoV laboratory confirmed cases, resulting in 712 deaths, were reported globally, with a majority of these cases from the Arabian Peninsula. This review summarises the current understanding of MERS-CoV, with special reference to the (i) genome structure, (ii) clinical features, (iii) diagnosis of infection and (iv) treatment and vaccine development.

Keywords: human coronavirus; MERS-CoV; clinical features; upper respiratory tract infections; lower respiratory tract infections; respiratory viruses

1. Introduction

Given the diversity of animal coronaviruses, it was not surprising when another human coronavirus was isolated from a patient presenting with severe respiratory illness in June 2012. The 60 year old man died as a result of renal and respiratory failure 11 days after admission to a hospital in Jeddah, Saudi Arabia [1]. The novel etiological agent was subsequently named Middle East Respiratory syndrome coronavirus (MERS-CoV) [2]. MERS-CoV is one of six known human coronaviruses that cause respiratory disease in humans and, with a mortality rate >35% [3], it is the first highly pathogenic human coronavirus to emerge since the global scare caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003.

With the Kingdom of Saudi Arabia the focal point of an ongoing MERS-CoV outbreak, the large number of religious pilgrims congregating annually in Saudi Arabia drastically increases the potential for the uncontrolled global spread of MERS-CoV infections [4]. In fact, infections have already been reported in more than 27 countries across the Middle East, Europe, North Africa and Asia [5-8].

This review focusses on the current information of MERS-CoV, with special reference to the genome structure, clinical features, diagnosis of infection and treatment and vaccine development. We also look at future prospects for MERS-CoV spread and prevention.

2. Genome Structure and Gene Functions

MERS-CoV, a lineage C Betacoronavirus (ßCoVs), has a positive-sense single-stranded RNA (ssRNA) genome about 30-kb in size [9, 10]. As of 2016, phylogenetic analysis of MERS-CoV has been...
done on 182 full-length genomes or multiple concatenated genome fragments, including 94 from humans and 88 from dromedary camels [11, 12]. The MERS-CoV genomes share more than 99% sequence identity, indicating a low mutation rate and low variance among the genomes. MERS-CoV genomes are roughly divided into two clades: clade A, which contains only a few strains, and clade B, to which most strains belong [12].

As with other CoV genomes, the first 5' two-thirds of the MERS-CoV genome consist of the replicase complex (ORF1a and ORF1b). The remaining 3' one-third encodes the structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as five accessory proteins (ORF3, ORF4a, ORF4b, ORF5 and ORF8b) that are not required for genome replication (Fig 1), but are likely involved in pathogenesis [9, 13-16]. The flanking regions of the genome contain the 5' and 3' untranslated regions (UTR) [13, 14]. Typical of the coronaviruses, the MERS-CoV accessory proteins do not share homology with any known host or virus protein, other than those of its closely related lineage C ßCoVs [12].

**Figure 1.** Schematic organization of human coronavirus (α and ß CoVs) genomes. HCoVs genomes are 26kb to 32kb in size. At the 5'-end, overlapping reading frames 1a and 1b (blue) make up two thirds of the genome. The remaining one third of the genome (expanded region) encodes for the structural (white) and accessory proteins (grey).

MERS-CoV structural and accessory protein-coding plasmids transiently transfected into cells, showed that while ORF 4b localised mostly in the nucleus, all of the other proteins (S, E, M, N, ORF 3, ORF 4a and ORF 5) localised to the cytoplasm [17]. Furthermore, studies with MERS-CoV deletion-mutants of ORFs 3 to 5 are attenuated for replication in human airway-derived (Calu-3) cells [18], and deletion-mutants of ORFs 4a and 4b are attenuated for replication in hepatic carcinoma-derived (Huh-7) cells [16, 19]. This clearly points to important putative roles for the MERS-CoV accessory proteins in viral replication, at least in an *in vitro* setting.

The principal response of mammalian cells to viral infection is the activation of the type I interferon (IFN)-mediated innate immune response through the production of type I IFNs (IFN-α and IFN-β). On the other hand, evasion of host innate immunity through IFN antagonism is a critical component of viral pathogenesis and is mediated by virus-encoded IFN antagonist proteins. Each
protein blocks one or more key signalling proteins in the IFN and NF-κB pathways to enhance viral replication and pathogenesis [20-23]. Coronaviruses have similarly evolved these mechanisms to impede or bypass the innate immunity of their hosts at various levels, which contribute to virulence. Various coronavirus proteins have previously been implicated in the disruption of signal transduction events required for the IFN response [24], often by interfering with the host’s type I interferon response.

Evidence of MERS-CoV inducing type I IFN only weakly and late in infection (9–15), suggests that MERS-CoV has also evolved mechanisms to evade the host immune system. In fact, MERS-CoV M, ORF 4a, ORF4b and ORF 5 proteins are reported to be strong IFN antagonists [17]. Further studies, using the transient overexpression of MERS-CoV accessory protein ORF4a, ORF4b, and ORF5, show that the MERS-CoV accessory proteins inhibit both type I IFN induction [17, 25, 26] and NF-kappaβ signalling pathways [26]. MERS-CoV ORF4a, a double-stranded RNA (dsRNA) binding protein [25], potentially acts as an antagonist of the antiviral activity of IFN via the inhibition of both the interferon production (IFN-β promoter activity, IRF-3/7 and NF-κB activation) and the ISRE promoter element signalling pathways [17]. MERS-CoV ORF4b, on the other hand, is an enzyme in the 2H-phosphoesterase (2H-PE) family with phosphodiesterase (PDE) activity. Even though MERS-CoV ORF4b is detected primarily in the nucleus of both infected and transfected cells [17, 25, 26], the expression levels of cytoplasmic MERS-CoV ORF4b are still sufficient to inhibit activation of RNase L, an interferon-induced potent antiviral activity [17, 25, 26]. MERS-CoV ORF4b is the first identified RNase L antagonist expressed by a human or bat coronavirus and provides a possible MERS-CoV mechanism for evasion of innate immunity by inhibiting the type I IFN and NF-kappaβ signalling pathways [16, 26].

3. Clinical Features

The median age of persons with laboratory-confirmed MERS-CoV infection is 49 years (range, <1-94 years); 65% of patients are males. The median time from illness onset to hospitalization is approximately 4 days, resulting in a median length of stay of 41 days [27]. Currently, among all patients, the morbidity rate is approximately 36% [3], with the median time from the onset of symptoms to death 11.5 days [28]. Chest radiography and computed tomography findings are generally consistent with viral pneumonitis and acute respiratory distress syndrome [29]. Laboratory findings include lymphopenia, thrombocytopenia and elevated lactate dehydrogenase levels [1, 27, 30-35], with some cases with a consumptive coagulopathy and elevations in creatinine, lactate dehydrogenase and liver enzymes [27, 29, 36].

The clinical spectrum of MERS-CoV infection ranges from asymptomatic infection [37-39] to rapidly progressive, acute respiratory distress syndrome, septic shock and multi-organ failure and death (see [28, 40] for review of clinical spectrum). Initial symptoms are often nonspecific and patients report general malaise, including low grade fever, chills, headache, nonproductive cough, dyspnea, and myalgia [41, 42]. Other symptoms can include sore throat and similar to SARS-CoV, MERS-CoV patients can also present with gastrointestinal symptoms such as anorexia, nausea and vomiting, abdominal pain and diarrhea [43-45]. Atypical presentations, including mild respiratory illness without fever and diarrheal illness, preceding the development of pneumonia have been documented [46]. Up to 50% of adult symptomatic patients require intensive care unit (ICU) treatment. These patients often show no sign of improvement and 40-70% typically require mechanical ventilation within the first week [28, 37, 47]. Renal replacement therapy is required for between 22-70% of critically ill patients [27, 30, 31, 36, 48], with the higher-end of the estimation possibly due to over-estimation as a result of hospital-acquired infections in patients with pre-existing renal disease [28, 31].

MERS-CoV is linked with more severe disease in older people, people with weakened immune systems, and those with chronic diseases such as cancer, chronic lung disease and diabetes. The majority of patients who are hospitalized with MERS-CoV infection had chronic co-morbidities such as obesity, diabetes, hypertension, cardiovascular diseases or end-stage renal disease [36, 49-51].
fact, about 75% of patients testing positive for MERS-CoV have at least one co-morbid disease; fatal cases are more likely to have an underlying condition (86% among fatal cases vs. 42% among recovered or asymptomatic cases) [29].

Interestingly, MERS-CoV cases have been reported mainly in adults [52], with children rarely affected [53, 54]. Even so, a recent case study of a MERS-CoV infected 9-month-old child, newly diagnosed to have infantile nephrotic syndrome, showed complications that resulted in severe respiratory symptoms, multi-organ dysfunction and death [55]. In another study of 11 pediatric cases that tested positive for MERS-CoV, the two symptomatic patients had Down’s syndrome and cystic fibrosis, respectively, indicating that severe disease could potentially occur in children with serious underlying conditions [39]. Even with these reported pediatric cases, data on infection in children remain scarce, making it difficult to ascertain whether MERS-CoV is really a predominantly adult disease, or whether it often presents differently in children.

Simultaneous infection of the respiratory tract with at least two viruses is common in hospitalized patients, and although it is not clear whether these infections are more, or less, severe than single virus infections [56], mixed clinical features are commonly observed [57]; this makes clinical diagnosis unreliable and severely limit epidemiological studies of etiological agents. Similar to other respiratory viruses, MERS-CoV has been found in combination with a second respiratory virus, such as Influenza A [45, 58] respiratory syncytial virus, para-influenza-3 or human metapneumovirus [59-61]. MERS-CoV infected patients requiring mechanical ventilation also exhibited a similar co-infection profile with nosocomial bacterial infections including, Klebsiella pneumoniae, Staphylococcus aureus, Acinetobacter species and Candida species [44, 62]. Preceding or concurrent viral respiratory tract infections can predispose the host to secondary co-infections from other microorganism throughout the airway. The mechanisms by which viruses promote these superinfections are diverse and replete [63]. As yet, not much is known as to how MERS-CoV damages the airway and dysregulate the host immune responses which, in turn, supports the adherence and invasion of other pathogens into normally sterile sites within the respiratory tract.

Neuromuscular complications are not rare during MERS treatment, and could simply have been underdiagnosed previously [64]. The first cases of severe neurological syndrome, characterized by varying degrees of consciousness, ataxia, focal motor deficit and bilateral hyper-intense lesions were reported from a retrospective study of patients in ICU [65]. Another subsequent small retrospective study in Saudi Arabia reported that 25.7% of MERS patients developed confusion and 8.6% experienced some kind of seizure [66]. To date, other cases with central nervous system involvement, including one case of intracerebral haemorrhage as a result of thrombocytopenia, disseminated intravascular coagulation and platelet dysfunction, one case of critical illness polyneuropathy [67] and four cases that included Bickerstaff’s encephalitis overlapping with Guillain-Barre syndrome, intensive-care-unit-acquired weakness, or other toxic or infectious neuropathies [64], have been reported. Neurological complications in the latter study did not appear concomitantly with respiratory symptoms, but were delayed by 2-3 weeks [64].

MERS-CoV can be detected in respiratory tract secretions, with tracheal secretions and broncho-alveolar lavage specimens containing a higher viral load than nasopharyngeal swabs. The virus has also been detected in feaces, serum and urine [45, 68-70]. Virus excretion peaks approximately 10 days after the onset of symptoms [45], but viable virus can be shed through respiratory secretions for up to 25 days from clinically fully recovered patients. In the healthcare setting, MERS-CoV has been isolated from environmental objects such as bed sheets, bedrails, IV fluid hangers and X-ray devices [71]. Another study also reported that MERS-CoV could survive for longer than two days at 20°C and 40% relative humidity, confirming the risk of contact or fomite transmission in healthcare settings [72]. Viral RNA, on the other hand, is detected for up to five days on environmental surfaces following the last positive PCR from patients’ respiratory samples; RNA was detected in samples from anterooms, medical devices and air-ventilating equipment [71], but this is not necessarily indicative of viable virus.
4. Diagnosis of infection

With no specific, reliable antiviral drug or vaccine approved for clinical use in MERS-CoV infections, rapid diagnostic tests are required to manage outbreaks of this virus. The first probe and primer sets for MERS-CoV detection by real-time RT-PCR were developed shortly after the initial reports of the disease [73, 74]. Other early diagnostic tools included virus culture in Vero and LLCMK2 cells [1, 75], but isolation and identification of viruses in cell culture is a slow, specialized and insensitive method [76].

Laboratory detection and confirmation of MERS-CoV infections has broadly included (i) molecular detection of MERS-CoV RNA, (ii) MERS-CoV antigen detection, or (iii) assays to identify a humoral response to prior MERS-CoV infection among humans [77] (Table 1). These assays have been used with varying degrees of success in terms of specificity, sensitivity, etc. Currently, MERS-CoV is primarily diagnosed using a real-time RT-PCR assay, with at least two different genomic targets required for a positive diagnosis according to the case definition announced by the WHO (http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/index.html)[78]. Among the probes and primers sets, those targeting upE and ORF1a show the highest sensitivity and remain the most widely used targets for MERS-CoV detection [73, 79]. A single positive target followed by gene sequencing is also considered positive; however, the current gene sequencing technique requires PCR amplicons, and the ability of conventional RT-PCR to produce a sequencing-quality template is generally lower than that of real-time RT-PCR [78, 80-84]. Molecular tests can detect nucleic acids derived from MERS-CoV in clinical respiratory, serum, and stool specimens [79, 85]. However, a major obstacle of nucleic acid-based tests, is that it requires specialized molecular techniques and equipment, and are therefore not appropriate for point-of-care testing or bedside diagnosis. For this reason, for effective diagnosis and treatment of MERS-CoV infection, it is necessary to develop alternative methods that can be adapted to rapid and reliable clinical detection of MERS-CoV antigens. Here, the most appropriate tests would be assays detecting viral antigens or antibodies in the infected host [85].

<table>
<thead>
<tr>
<th>Method used for detection</th>
<th>Sensitivity/ Specificity/ Viral Target gene</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT-rtPCR</td>
<td>Sensitivity for upE is 3.4 copies per reaction (95% confidence interval (CI): 2.5-6.9 copies) or 291 copies/mL of sample.</td>
<td>[73]</td>
</tr>
<tr>
<td></td>
<td>No cross-reactivity was observed with coronaviruses OC43, NL63, 229E, SARS-CoV, nor with 92 clinical specimens containing common human respiratory viruses.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Targeting regions upstream of the E gene (upE) or within open reading frame (ORF) 1b, respectively.</td>
<td></td>
</tr>
<tr>
<td>rtRT-PCR</td>
<td>Sensitivity to widely used upE gene as well as a ORF 1a&amp;b was introduced</td>
<td>[79]</td>
</tr>
</tbody>
</table>

Table 1. Detection methods of MERS-CoV
No false-positive amplifications were obtained with other human coronaviruses or common respiratory viral pathogens or with 336 diverse clinical specimens from non-MERS-CoV cases; specimens from two confirmed MERS-CoV cases were positive with all assay signatures.

Two novel signatures used one that targets the MERS-CoV N gene in combination with the upE test. The other a positive test to add to an efficient MERS-CoV kit.

<table>
<thead>
<tr>
<th>Assay Type</th>
<th>Property 1</th>
<th>Property 2</th>
<th>Property 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT-Sequence-Validated-LAMP Assays</td>
<td>Could detect 0.02 to 0.2 plaque forming units (PFU) (5 to 50 PFU/ml) of MERS-CoV in infected cell culture supernatants.</td>
<td>Did not cross-react with common human respiratory pathogens.</td>
<td>Assay designed to amplify the MERS-CoV N gene in combination with the upE test.</td>
</tr>
<tr>
<td>RT-LAMP</td>
<td>Capable of detecting as few as 3.4 copies of MERS-CoV RNA; Assay exhibited sensitivity similar to that of MERS-CoV real-time RT-PCR.</td>
<td>No cross-reaction to other respiratory viruses.</td>
<td>Assay designed to amplify the partial nucleocapsid gene of MERS-CoV</td>
</tr>
<tr>
<td>rt-RPA</td>
<td>Highly sensitive, is able to detect 10 MERS-CoV RNA copies with a more rapid detection time than MERS-RT-PCR.</td>
<td>No cross-reaction to other respiratory viruses including HCoVs.</td>
<td>Assay designed to amplify the partial nucleocapsid gene of MERS-CoV</td>
</tr>
<tr>
<td>mAb Test</td>
<td>Rapid detection and cost effective ELISA</td>
<td>High specificity used to detect the MERS-CoV nucleocapsid protein</td>
<td></td>
</tr>
<tr>
<td>Immuno-chromatographic tool</td>
<td>Highly sensitive,</td>
<td>No cross reactivity with other respiratory pathogens observed in vitro and in silico</td>
<td>Detects recombinant MERS-CoV N protein</td>
</tr>
<tr>
<td>Immunofluorescence Assay</td>
<td>Highly sensitive, antigen based detection</td>
<td>Cross reactivity seen with convalescent SARS patient (sera)</td>
<td>Assay used both whole virus and S1 portion of the spike protein</td>
</tr>
<tr>
<td>ppNT Assay</td>
<td>Highly sensitive, more sensitive that MNT test</td>
<td>Lack of MERS neutralizing activity indicated high specificity by this assay. No cross reactivity seen with SARS-CoV</td>
<td>Assay was designed for two different genes used: a codon optimised spike gene and a HIV/MERS pseudoparticle was generated</td>
</tr>
</tbody>
</table>
MNT Test
1. Highly sensitive less so than ppNT assay
2. Highly specific, as SARS-CoV antigen was not detected compared to MERS.
3. Test designed to detect IgG antibodies generated when using the RBD of the S1 subunit of the spike gene

Protein Microarray
1. Highly sensitive assay using protein microarray technology to detect IgG and IgM antibodies
2. No cross-reactivity seen with sera of patients that had been exposed to four common HCoVs.
3. Assay designed to use the S1 receptor-binding subunit of the spike protein of MERS and SARS as antigens.

One pot RT-LAMP
1. Capable of detecting four viral copies MERS within 60 mins
2. No cross-reaction to the other acute respiratory disease viruses (influenza type A (H1N1 and H3N2), type B, HCoV-229E, and human metapneumovirus)
3. Six sets of primers designed specifically to amplify the MERS-CoV genes

RT-iiPCR assays
1. Could detect $3.7 \times 10^{-1}$ plaque forming units (PFU) of MERS-CoV in infected cell culture supernatants and sputum samples.
2. Viral nucleic acids extracted from infected cultures that contained HCoV-229E, HCoV-OC43, FIPV, influenza virus types A and B strains yielded negative results, indicating no cross-reactivity.
3. Targeting regions upstream of the E gene (upE) or within open reading frame (ORF) 1b

Powercheck MERS Assay
1. 95% limits of detection of assay for the upE and ORF1a were 16.2 copies/μL and 8.2 copies/μL, respectively.
2. No cross-reactivity with other respiratory pathogens observed in vitro and in silico
3. Targeting regions upstream of the E gene (upE) or within open reading frame (ORF) 1b

acpcPNA-AgNP aggregation assay
1. Probe designed for targets makes this assay highly specific. Limit of detection found to be 1.53nM
2. Cross-reactivity with other CoVs was not evaluated
3. Synthetic oligonucleotides were designed to target MERS

mCoV-MS
1. Highly sensitive, multiplex PCR based to target specific genes in HCoVs
Cross reactivity with other respiratory pathogens was not evaluated.

Targeting regions upstream of the E gene (upE) or within open reading frame (ORF) 1b

Duplex-RT-PCR method

Highly sensitive, simultaneous detection of MERS and SARS viruses.

Cross reactivity with other respiratory pathogens was not evaluated.

Primers and probes that target the conserved spike S2 region of SARS-CoV, MERS-CoV, and their related bat CoVs were used.

5. Animal Models

Not only are laboratory animal species often used as models for human disease progression, they are also needed to study and evaluate novel therapies against emerging viruses [103]. Studies have shown that rabbits [104], ferrets [105], Syrian hamsters [106] and wild-type mice [107] are not suitable as models of MERS-CoV infection. More recently, three transgenic mouse models for MERS-CoV infection have been developed. In the first, a modified adenovirus expressing human DPP4 (huDPP4) is introduced intranasally to mice which results in the expression of huDPP4 in all cells of the lung, not just those that natively express DPP4. In this model, mice show transient human DPP4 expression and mild lung disease. A concern with this model is that cells constitutively expressing DPP4 will be infected and the role of a broader infection of all cell types may change pathogenesis [108]. In the second model, a transgenic mouse was produced that expresses huDPP4 systemically. In this model, MERS-CoV infection leads to high levels of viral RNA and inflammation in the lungs, but unfortunately, significant inflammation and viral RNA is also detected in the brains of infected mice, which represent a non-physiological expression pattern [109]. In the third model, a novel transgenic humanized mouse model was generated by replacing the mouse DPP4 coding sequence with that encoding huDPP4, ensuring correct physiological expression of huDPP4. Mice in this model show lung pathology consistent with the radiographic findings of interstitial pneumonia and significant lung disease as seen in humans infected with MERS-CoV. This suggests that this mouse model recapitulates pathological sequelae that are seen in MERS-CoV infection of humans. Importantly, unlike what is seen in other mouse models of MERS-CoV infection, virus replication...
and pathology in the huDPP4 mice is localized in the lungs and no inflammation develops in the
brain, ensuring a more physiological accurate model of the human disease [110].

Non-human primate models, including the rhesus macaque [111-113] and common marmoset
[114] have also been reported as suitable animal models of MERS-CoV infection. Even though both
species are susceptible to MERS-CoV infection, the extent of virus replication and severity of disease
vary [103]. Rhesus macaques infected with MERS-CoV via intra-tracheal inoculation show clinical
signs of disease, virus replication, histological lesions and neutralizing antibody production,
indicating that this monkey model is suitable for studies of MERS-CoV infection [113]. On the other
hand, the common marmoset reproduces several, but not all, features of MERS-CoV infection, and
can potentially be used to evaluate novel therapies for human use [103, 114].

6. Treatment and Vaccine development

When no vaccines or specific antiviral drugs are available during an outbreak, nonspecific
therapeutic interventions are often introduced to prevent severe morbidity and mortality. However,
for this to be done effectively, a basic understanding of the pathogenesis of the disease is required
and interventions are implemented based on observations of the clinical course of disease and
complications. Due to the nature of many diseases, however, it is often not possible to assess, or
systematically compare, different therapeutic approaches during an outbreak [115]. Similarly, in the
case of MERS-CoV it is necessary to monitor epidemic patterns and investigate the spread of
infections to efficiently identify, control and prevent possible epidemics. For MERS-CoV infections,
supportive care, which includes rest, fluids and analgesics are used, and mainly depends on the
 provision of organ support and management of complications [116-118]. Broad-spectrum
antimicrobials, antivirals [119, 120], interferon-α2b (96) and antifungals can be used to minimize the
risk of co-infection with opportunistic pathogens [116, 118].

Interestingly, combination treatment with ribavirin and interferons inhibits MERS-CoV
replication in vitro, and it was also shown to improve clinical outcomes in MERS-CoV-infected non-
human primates. However, this treatment in the rhesus macaques was initiated very soon after viral
challenge (~8 h), resulting in reduced disease severity in the rhesus macaque model. This appears to
simulate mild-to-moderate human MERS-CoV cases, making it difficult to extrapolate the outcome
of this early intervention in severe human cases. Even though the study authors recommended that
combined IFN-α2b and ribavirin therapy should be considered as an early intervention therapy for
MERS-CoV [112], we also need to keep in mind that due to the limited effective therapeutic window
of opportunity, broad spectrum antivirals might not be sufficient to treat severe MERS-CoV patients
[120].

Resveratrol has been shown to inhibited various human viruses in vivo and in vitro, including
influenza virus, Epstein Barr virus, herpes simplex virus, respiratory syncytial virus, HIV-1, varicella
zoster virus, enterovirus 71, human metapneumo-virus, human rhinovirus 16, polyomavirus and
cytomegalovirus [(121, 122) for review]. The antiviral effects of resveratrol are mainly associated with
the inhibition of viral replication, protein synthesis, gene expression, and/or nucleic acid synthesis
[121-123]. In an in vitro study, resveratrol was shown to significantly inhibit MERS-CoV infection,
most likely due to the observed inhibition of MERS-CoV nucleocapsid (N) protein expression [124],
a multifunctional protein essential for CoV replication [125]. Furthermore, resveratrol down-
regulated apoptosis induced by MERS-CoV, thereby prolonging cellular survival post-infection [124].
Although the beneficial roles of resveratrol in several viral diseases have been well documented,
adverse effects have been also been reported, including increasing viral RNA replication during Hep-
C virus infection in vitro (OR6 cells) [126], strong cytotoxicity in cultured cells [127], as well as
enhanced HBV transcription and replication in vitro and in vivo [128]. Clearly, the antiviral potential
of resveratrol in MERS-CoV infections needs to be studied more extensively, but based on the various
unintended negative effects, this needs to proceed with caution.

More recently, [129] reported that in an in vitro test, low-micromolar concentrations of
alisporivir, a non-immunosuppressive cyclosporin A-analog, inhibit the replication of four different
coronaviruses, including MERS-CoV. In this study, ribavirin was found to further potentiate the
antiviral effect of alisporivir in the *in vitro* infection models, which warrants the further exploration
of Cyp inhibitors as potential host-directed, broad-spectrum inhibitors of coronavirus replication
[129]. 3C-like protease (3CL\(\text{pro}\)) - analogous to picornavirus 3C protease (3C\(\text{pro}\)) - is functionally
important in the CoV replication cycle [130] and is thus regarded as a validated drug target.
Peptidomimetic inhibitors of enterovirus 3C\(\text{pro}\) (6b, 6c and 6d) inhibited MERS-CoV 3CL\(\text{pro}\) and in
MERS-CoV-infected cells, the inhibitors showed antiviral activity by downregulating viral protein
production in cells, as well as reducing release of infectious viral particles into culture supernatants.
These compounds exhibited good selectivity index and should be investigated further as, not only an
inhibitor of MERS-CoV replication and infections, but also as broad-spectrum antiviral activity drugs
against other CoVs and picornaviruses [131]. Our laboratory has also previously screened the ZINC
drugs-now library for candidates with potential anti-3CL\(\text{pro}\) activity with a consensus high-
throughput pharmacophore modelling and molecular docking approach. Molecular dynamics was
used to confirm results obtained from structure-based techniques, resulting in a highly defined hit-
list of 19 compounds which represent valuable scaffolds that could be used as a basis for future anti-
coronaviral inhibitor discovery experiments [47, 132]. Even with all of these potential anti-MERS-
CoV candidates, no experimental interventions have demonstrated significant benefit in acutely ill
patients in a consistent or controlled manner. Therefore, supportive management, adapted from
guidelines developed for SARS-CoV, has thus far been the mainstay of MERS-CoV treatment [133].

Because of the highly sophisticated immune evasion mechanisms of viral pathogens, human
candidate development remains a major challenge [134]. In addition, the development of safe and
effective coronavirus vaccines has been even more challenging, being curtailed by major obstacles,
including, (1) coronavirus immunity often wanes rapidly, (2) individuals needing to be protected
include the elderly, and (3) vaccines may exacerbate rather than prevent coronavirus lung
immunopathology [135, 136]. Various vaccines against MERS-CoV have been designed, some of
which are currently being tested in clinical trials (*Table 2*). All of the MERS-CoV structural proteins
could potentially induce neutralizing antibodies and protective responses. However, prior to
identification of the major neutralizing antibody-inducing epitopes, inactivated virus could be used
in the production of first-generation vaccines; this is an easy first-response approach since it is
relatively simple to produce whole killed virus particles [137]. With the many safety concerns
associated with the production of inactivated vaccines [138-140], these type of vaccines must
preferably be replaced by safer and more effective neutralizing epitope-based vaccines, as soon as
the fragments containing the neutralizing epitopes are identified [137]. Current MERS-CoV vaccines
provide effective protection in a few animal models [141-145].
Table 2. MERS-CoV vaccines developed (adapted from [133, 146])

<table>
<thead>
<tr>
<th>Vaccine Categories</th>
<th>Target Antigen</th>
<th>Immunization</th>
<th>Animal Model</th>
<th>Immunogenicity</th>
<th>Stage of development</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-MERS-CoV monoclonal antibodies</td>
<td>Surface (S) glycoprotein</td>
<td>Passive</td>
<td>marmosets</td>
<td>Animals developed pneumonia, high viral titre detected in lungs</td>
<td>Preclinical: <em>in vivo</em>, efficacy stage</td>
<td>[147-149]</td>
</tr>
<tr>
<td>Human polyclonal anti-MERS-CoV antibodies</td>
<td>Virus structural proteins</td>
<td>Passive</td>
<td>Ad5-hDPP4-transduced mouse</td>
<td>Nab developed to reduce viral titres post exposure</td>
<td>Preclinical: <em>in vivo</em>, efficacy stage</td>
<td>[150]</td>
</tr>
<tr>
<td>Inactivated virion vaccines</td>
<td>MERS-CoV</td>
<td>Active</td>
<td>hDPP4-transgenic mice</td>
<td>Nab produced without adjuvant, T-cell response not done</td>
<td>Preclinical: <em>in vivo</em>, efficacy stage</td>
<td>[151]</td>
</tr>
<tr>
<td>Live attenuated vaccines (deleted E protein; mutated in nsp14)</td>
<td>rMERS-CoV-ΔE</td>
<td>Active</td>
<td>Not tested</td>
<td>Not indicated</td>
<td>Preclinical development: <em>in-vitro</em></td>
<td>[19]</td>
</tr>
<tr>
<td>Recombinant viral vectors (MVA, Adenovirus, Parainfluenza virus, Measles, Rabies)</td>
<td>S and SoL proteins</td>
<td>Active</td>
<td>Ad/hDPP4-mice Camels</td>
<td>Nab in mice, antigen specific humoral and in some case T cell immune responses</td>
<td>Preclinical: <em>in-vitro</em>, efficacy stage</td>
<td>[152-157]</td>
</tr>
<tr>
<td>Vaccine Type</td>
<td>Target Protein</td>
<td>Activity</td>
<td>Description</td>
<td>Stage Details</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Replicon particles</td>
<td>S protein</td>
<td>Active</td>
<td>Ad/hDPP4-mice: mice transduced with hDPP4 in an adenovirus vector; Nab produced, mice developed progressive pneumonia with virus replication detected in airways</td>
<td>Preclinical: in vivo, efficacy stage [158, 159]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuelan (VRP-S)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subunit vaccines</td>
<td>S or S1 protein with various amino acid residues</td>
<td>Active</td>
<td>- Ad/hDPP4-transgenic -hDPP4: mice; Rabbits protected from MERS-CoV; Good T-cell response in mice. Tg-Mice protected from MERS-CoV</td>
<td>Preclinical: in-vitro, efficacy stage [145, 160-165]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA vaccines</td>
<td>S protein</td>
<td>Active</td>
<td>NHP: Rhesus Macaques Mice; Cellular immune response and Nab response in mice, NHPs and camels.</td>
<td>Phase 1 clinical trials [166]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA prime/Protein-boost Vaccines</td>
<td>S and S1 protein</td>
<td>Active</td>
<td>NHP: Rhesus Macaques Mice; Nab response seen in mice and NHPs</td>
<td>Preclinical: in-vitro, efficacy stage [167]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VLPs</td>
<td>S, M, E</td>
<td>Active</td>
<td>NHP: Rhesus Macaques Mice; Virus specific Nab and IgG antibody response against the RBD</td>
<td>Preclinical: in vivo, efficacy stage [168]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nanoparticle vaccine</td>
<td>S protein</td>
<td>Active</td>
<td>Mice; NAB with the presence of adjuvant (M1 and Alum)</td>
<td>Preclinical: in vivo, efficacy stage [169, 170]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ad: Adenovirus; Ad/hDPP4-mice: mice transduced with hDPP4 in an adenovirus vector; Alum: aluminum hydroxide (adjuvant); ΔE: truncated envelope protein, hDPP4: human dipeptidyl peptidase 4; M1: matrix protein 1 (adjuvant); MERS-CoV: Middle East Respiratory Syndrome Coronavirus; M: membrane protein; MVA: modified vaccinia virus Ankara; N: nucleocapsid protein; Nab: neutralizing antibody; NHP: non-human primates; rMERS-CoV: recombinant Middle East
respiratory syndrome coronavirus; rNTD: recombinant N-terminal domain; RBD: receptor-binding domain; rRBD: recombinant RBD; RBD-Fc: RBD fused to the human IgG antibody crystallizable fragment; S: spike protein; S1: S1 domain of the spike protein, SolS: spike protein lacking transmembrane domain; Tg-mice: transgenic mice; VRP: virus replicon particle; VLP’s: virus like particles
7. Future perspective

The emergence of Middle East respiratory syndrome (MERS) and the discovery of the MERS coronavirus (MERS-CoV) in 2012 suggests that another SARS-like epidemic is occurring. Unlike the severe acute respiratory syndrome (SARS) epidemic, which rapidly disappeared in less than one year, MERS has persisted for over three years. More than 2000 cases of MERS have been reported worldwide, and the disease carries a worryingly high fatality rate of >30% [12]. While this number seems low, the virus remains a global threat due to its propensity to cause severe disease in patients with underlying medical conditions and its apparent ability to readily spread within hospital settings [171]. In addition, the pattern of MERS-CoV lineages is more consistent with the movement of infected livestock or animal products [172] and epidemiological evidence suggests that it is periodically introduced into human populations [173, 174], which increases the risk for various future pandemics.

Even though the clinical outcomes of MERS-CoV infections are well documented, more comprehensive population-based studies are required to determine the involvement of MERS-CoV in other body systems. Also, the continued development of technologies to routinely and accurately identify asymptomatic MERS-CoV infections will shed light on the true incidence of this virus in the human population. It would appear the MERS-CoV has been circulating in the human population for greater than one year without detection and suggests independent transmission from an unknown source. However, as discussed previously with regard to the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, other evolutionary aspects, such as mutation rates and selection pressure, should be considered to understand the evolutionary dynamics of MERS-CoV [175-178]. Possibly different molecular clock rates of MERS-CoV in animal hosts and humans may also have to be taken into account. Similarly to the genomic evolution of influenza A viruses [179], MERS-CoV might experience different evolutionary courses in different hosts. To better understand these dynamics, the chain of MERS-CoV zoonotic transmissions should be further clarified [175].

As with other HCoVs, a detailed manipulation of the MERS-CoV genome to understand the role of the MERS-CoV viral genes in pathogenesis and replication, and for the subsequent development of MERS-CoV as a vaccine vector, is needed. The development of MERS-CoV full-length infectious clones [18, 19, 180] already allows for the systematic experimental study of the roles of the various corresponding MERS-CoV proteins, which should lead to a better understanding of the role of the viral genes in infectivity and pathogenicity [181]. This manipulation of the virus genome also provides a reverse genetics platform that could lead to the future development of MERS-CoV-based vector vaccines [182].

As a result of the increase in MERS spread, the WHO and CDC have released various case definitions to allow for the likelihood of a pandemic threat to be reduced. Fever, pneumonia, and acute respiratory distress syndrome with a history of travel to the Arab Peninsula are some of the symptoms that are used to diagnose a MERS-CoV infection. Due to the increase in nosocomial infections, health care workers are also advised to be aware of any upper respiratory tract infections and exposure to MERS-CoV-positive individuals [183]. For the foreseeable future, important measures to prevent nosocomial outbreaks should include good compliance with appropriate personal protection equipment by health-care workers when managing patients with suspected and confirmed MERS-CoV infection, early diagnosis, prompt isolation of infected patients, and improvement of ventilation in health-care facilities [184, 185].

Acknowledgments: BCF receives funding from the National Research Foundation (South Africa) and the University of the Western Cape Senate Research Fund. Any opinion, findings and conclusions or recommendations expressed in this material are those of the authors and therefore the NRF does not accept any liability in regard thereto.

Author Contributions: BCF and AC made an equal contribution in the writing of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the manuscript.
References


vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. 


